EIF4G1 and melanoma: Currently available eIF4F inhibitors have liabilities, including low potency, lack of selectivity or poor pharmacological properties.5 Here we use the novel small molecule inhibitor of eIF4G1, named SBI-756, to target the eIF4F translation initiation complex.19 SBI-756 is a small molecule that binds to eIF4G1 and prevents its interaction with eIF4E.19 In our previous study, SBI-756 inhibited melanoma in vitro and in vivo.19